Not recruitingISRCTN49376288

Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks.

Research studyAges 18–60Multiple countriesDepression

The study in practice

Understand this study

Listed age limits: 18 years to 60 years.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNot clearly listed

Recruitment status: Not recruiting
Enrollment listed in the registry: Not clearly listed
Sponsor: Institut de Recherches Internationales Servier (France)
Sponsor type: Research institute
Study type: Other
Intervention type: Other / unclear
Study phase: Not clearly listed
Locations: France, Austria, Germany, ...
Age range: From 18 Years to 60 Years
Official registry ID: ISRCTN49376288
Official title: Show the full official title
Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks.

Not recruiting

Austria · France · Germany

3 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Institut de Recherches Internationales Servier (France), a research institute.

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as not recruiting.